Nontuberculous mycobacteria in the HIV infected patient

Clinics in Chest Medicine

Volumn 23, Issue 3, 2002, Pages 665-674

  Jones, Denis ^a   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAVIRDINE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; INDINAVIR; ISONIAZID; LOPINAVIR; MACROLIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STREPTOMYCIN; SULFAMETHOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LUNG INFECTION; MYCOBACTERIOSIS; MYCOBACTERIUM GENAVENSE; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM XENOPEI; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL; TUBERCULOSIS, PULMONARY;

EID: 0036738087     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00015-1     Document Type: Review

References (72)

1. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS related disseminated Mycobacterium avium complex after twelve months anti-mycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998;178:1446-9.
2. Agins BD, Boman DS, Spicehaudler D, et al. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159(4):784-7.
3. Beggs ML, Crawford JT, Eisenach KD. Isolation and sequencing of the replication region of Mycobacterium avium plasmid pLR7. J Bacter 1995;177:4836-40.
4. Benson CA, Ellner JJ. Mycobacterium avium Complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993;17:7-20.
5. Bermudez LE, et al. An animal model of mycobacterium avium complex disseminated infection after colonization of the intestinal tract. J Infect Dis 1992;165: 75-9.
6. Chaisson RE, et al. Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 1992;146:285-9.
7. Chaisson RE, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Annals Internal Med 1994;121: 905-11.
8. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997;11(3):311-7.
9. Chin DP, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169:289-95.
10. Cinti SK, Kaul DR, Sax PE. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis 2000;30:511-4.
11. Corbett EL, Churchyard GJ, Hay M. The impact of HIV infection on Mycobacterium Kansasii disease in South African gold miners. Am J Respir Crit Care 1999;160:10-14.
12. Currier JS, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. Annals Internal Med 2000;133(7):493-503.
13. Dautzenberg B, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144:564-9.
14. Donnabella V, Salazar-Schicchi J, Bonk S. Increasing incidence of Mycobacterium Xenopi at Bellevue hospital: an emerging pathogen or a product of improved laboratory methods. Chest 2000;118:1365-70.
15. Dubé MP, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997;176(5):1225-32.
16. Dubé MP, et al. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. Clin Infect Dis 1999;28(1): 136-38.
17. Dunne M, Fessel J, Kumar P. A randomized, double blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with HIV. CID 2000;31: 1245-52.
18. Eckburg PB, Buadu EO, Stark P. Clinical and chest radiographic findings among persons with sputum culture positive for Mycobacterium gordonae. Chest 2000;117.
19. EI-Sadr WM, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000;342(15): 1085-92.
20. Ellner PD, et al. Rapid detection and identification of pathogenic mycobacteria by combining radiometric and nucleic acid probe methods. J Clin Microbiol 1988;26:1349-52.
21. French AL, Benator DA, Gordin FM. Nontuberculous mycobacterial infections. Med Clin N Am 1997;81: 361-79.
22. Ghassemi M, et al. Human immunodeficiency virus and Mycobacterium avium complex coinfection of monocytoid cells results in reciprocal enhancement of multiplication. J Infect Dis 1995;171(1):68-73.
23. Gordin FM, Sullam PM, Shafran SD. Randomized placebo controlled study of rifabutin added to a regimen of Clarithromycin and Ethambutol for treatment of disseminated infection with mycobacterium avium complex. Clin Infect Dis 1999;28:1080-5.
24. Havlik JAJ, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends 1992;165:577-80.
25. Havlir DV, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335: 392-98.
26. Havlir DV, et al. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. J Infect Dis 1998;177(3):595-99.
27. Havlir DV, Ellner JJ. Mycobacterium Avium complex. In: Mandell GL, editor. Principles and practice of infectious diseases. Infectious diseases and their etiologic agents. Philadelphia (PA): Churchill Livingston; 2000. p. 2616-28.
28. Hirschel B, Chang HR, Mach N. Fatal infection with a novel unidentified mycobacterium in a man with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:109-13.
29. Hocqueloux L, Lesprit P, Hermann JL, et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. Chest 1998; 113(2):542-8.
30. Horsburgh CRJ. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332-8.
31. Horsburgh Jr CR, et al. Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus infection. J Infect Dis 1994;170(2):362-7.
32. Horsburgh CR, Hanson DL, Thompson SE. Decreased risk of disseminated M.avium complex in persons with prior TB. In: Abstracts of 1995 International Conference of the American Thoracic Society. Seattle. 1995.
33. Jacobson MA, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991;164:994-8.
34. Johnson JL, et al. Altered IL-1 expression and compartmentalization in monocytes from patients with AIDS stimulated with Mycobacterium avium complex. J Clin Immunol 1997;17(5):387-95.
35. Kalayjian RC, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1995;20(5):1186-94.
36. Kallenius G, et al. Human immunodeficiency virus type 1 enhances intracellular growth of Mycobacterium avium in human macrophages. Infect Immun 1992;60:2453-8.
37. Kaplan JE, Hanson D, Dworkin MS. Epidemiology of human immunodeficiency virus associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30: 5-14.
38. Kiehn TE, Edwards FF. Rapid identification using a specific DNA probe of Mycobacterium avium complex from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1987;25:1551-2.
39. Ledergerber B, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353(9156):863-8.
40. Levine B, Chaisson RE. Mycobacterium Kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus infection. Annals Internal Med 1991;114:861.
41. Lillo M, Orengo S, Cernoch P. Pulmonary and disseminated infection due to Mycobacterium Kansasii: a decade of experience. Rev Infect Dis 1990;12(5): 760-7.
42. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals Internal Med 1999;131(2):81-7.
43. Macher AM, et al. Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Annals Internal Med 1983;99:782-5.
44. May T, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 1997;25(3):621-9.
45. Monill JM, Franquet T, Sambeat MA. Mycobacterium genavense infection in AIDS: imaging findings in eight patients. Euro Radiol 2001;11:193-6.
46. Morrissey AB, et al. Absence of Mycobacterium avium complex disease in patients with AIDS in Uganda. J AIDS Human Retrovirol 1992;5:477-8.
47. Murray HW, et al. T lymphocyte responses to mycobacterial antigen in AIDS patients with disseminated Mycobacterium avium-Mycobacterium intracellular infection. Chest 1988;93(5):922-5.
48. Narita M, Ashlin D, Hollender ES. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
49. Nightingale SD, Byrd LT, Southem PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165(6):1082-5.
50. Nightingale SD, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
51. O'Brien DP, Currie BJ, Krause VL Nontuberculous Mycobacterial disease in Northern Australia: a case series and review of the literature. Clin Infect Dis 2000;31:958-68.
52. Okello DO, Sewankambo N, Goodgame R, et al. Absence of Bacteremia with Mycobacterium avium-intracellulare in Ugandan patients with AIDS. J Infect Dis 1990;162:208-10.
53. Oldfield ECI, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1997;26: 611-19.
54. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338(13):853-60.
55. Pethel ML, Falkinham III JO. Plasmid-influenced changes in Mycobacterium avium catalase activity. Infect Immun 1989;57:1714-18.
56. Pierce M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335(6):384-91.
57. Price P, Stone SF. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Human Immunol 2001;62:157-64.
58. Race EM, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351 (9098):252-5.
59. Research Committe of the British Thoracic Society. First randomized trial of treatments for pulmonary disease caused by M.intracellulare, M malmoense and M.xenopi in HIV negative patients: rifampin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-72.
60. Salfinger M, et al. Comparison of three methods for recovery of Mycobacterium avium complex from blood specimens. 1988;26:1225-6.
61. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-S25.
62. Sturgill-Koszycki S, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994;263(5147): 678-81.
63. Torriani F, et al. Evidence that HAART-induced immune recovery vitritis in CMV retinitis patients is immune mediated. Presented at the 12th World AIDS Conference. Geneva, Switzerland. 1998.
64. Tortoli EST, Lavinia F. Evaluation of reformulated cheiluminescent DNA probe for culture identification of Mycobacterium Kansasii. J Clinl Microbiol 1996; 34:2838-40.
65. USPHS/IDSA. 2001 USPHS/IDSA guidelines for the prevention and treatment of opportunistic infections in persons infected with human immunodeficiency virus, revision 13. 2001. p. 1-64.
66. Wallace Jr RJ. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society statement. American Journal of Respiratory and Critical Care 1997;156(Suppl):S1-S25.
67. Williams PL, Currier JS, Swindells S. Joint effects of HIV 1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. AIDS 1999; 13:1035-44.
68. Witzig RS, Fazal BA, Mera RM. Clinical manifestations and implications of coinfection with Mycobacterium Kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995;21:77.
69. Wolinski E. Mycobacterial diseases other than tuberculosis. Clinical Infectious Diseases 1992;15:1-12.
70. Yates MD, Pozniak A, Uttley AHC. Isolation of enviromental mycobacteria from clinical specimens in South East England, 1973-1993. Internatl J Tuberc Lung Dis 1997;75-80.
71. Young LS, et al. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
72. Zakowski P, et al. Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency. J Am Med Assoc 1982;248:2980-2.